コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 arding the optimal formulations and doses of aminosalicylates.
2 drug use were 0.82 (95% CI, 0.42-1.61) for 5-aminosalicylates 0.48 (95% CI, 0.15-1.50) for corticoste
3 e odds ratios were 0.8 (95% CI, 0.5-1.1) for aminosalicylates, 0.5 (95% CI, 0.3-0.9) for immunomodula
5 statements focused on 5 main drug classes: 5-aminosalicylate (5-ASA), corticosteroids, immunosuppress
6 mild flares controlled with initiation of 5'-aminosalicylates (5'-ASA), and two patients (6%) require
7 the association between adherence to oral 5-aminosalicylates (5-ASAs) and all-cause costs and health
8 e relationship with CD mortality was 0.7 for aminosalicylates (95% CI, 0.5-1.1), 1.3 (95% CI, 0.9-1.9
9 tions or to anti-inflammatory therapy with 5-aminosalicylates, although a few require corticosteroids
10 local delivery of existing agents, such as 5-aminosalicylate and corticosteroids, and on novel immuno
11 omen with IBD; 31.2% of women discontinued 5-aminosalicylates and 24.6% discontinued azathioprine/6-m
12 o the overall safety of medical therapy with aminosalicylates and immunomodulators during pregnancy.
13 regarding the optimization of treatment with aminosalicylates and the short- and long-term benefits o
14 st to revolutionary) clinical data regarding aminosalicylates, antibiotics, and steroids as inductive
15 women with IBD, and all prescriptions for 5-aminosalicylates azathioprine/6-mercaptopurine, and cort
16 and in children exposed or not exposed to 5-aminosalicylates, azathioprine/6-mercaptopurine, or cort
17 udesonide, have a greater acute benefit than aminosalicylates, but this benefit does not translate in
19 ot responsive to conventional treatment with aminosalicylates, corticosteroids and immune modulators.
20 strate that mesalamine, an anti-inflammatory aminosalicylate, dose-dependently inhibits IL-1-stimulat
21 ent data support the overall safety of the 5-aminosalicylate drugs as well as azothiaprine/6-mercapto
22 spite the fact that, aside from a variety of aminosalicylate formulations, no new therapies have been
23 d drugs, except for a 7% decline in use of 5-aminosalicylate in CD and no change in steroid use for C
25 f those patients most likely to benefit from aminosalicylate therapies, the risks of relapse from usi
27 the advances and controversies pertaining to aminosalicylate therapy, corticosteroids, cyclosporine,
31 g the most interesting chemotypes were the 5-aminosalicylates, which docked in two distinct but overl
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。